Premium
The pediatric solid organ transplant experience with COVID‐19: An initial multi‐center, multi‐organ case series
Author(s) -
Goss Matthew B.,
Galván N. Thao N.,
Ruan Wenly,
Munoz Flor M.,
Brewer Eileen D.,
O’Mahony Christine A.,
MelicoffPortillo Ernestina,
Dreyer William J.,
Miloh Tamir A.,
Cigarroa Francisco G.,
Ranch Daniel,
Yoeli Dor,
Adams Megan A.,
Koohmaraie Sarah,
Harter Diana M.,
Rana Abbas,
Cotton Ronald T.,
Carter Beth,
Patel Shreena,
Moreno Nicolas F.,
Leung Daniel H.,
Goss John A.
Publication year - 2021
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13868
Subject(s) - medicine , immunosuppression , asymptomatic , pediatrics , organ transplantation , sore throat , population , surgery , transplantation , environmental health
The clinical course of COVID‐19 in pediatric solid organ transplant recipients remains ambiguous. Though preliminary experiences with adult transplant recipients have been published, literature centered on the pediatric population is limited. We herein report a multi‐center, multi‐organ cohort analysis of COVID‐19‐positive transplant recipients ≤ 18 years at time of transplant. Data were collected via institutions’ respective electronic medical record systems. Local review boards approved this cross‐institutional study. Among 5 transplant centers, 26 patients (62% male) were reviewed with a median age of 8 years. Six were heart recipients, 8 kidney, 10 liver, and 2 lung. Presenting symptoms included cough (n = 12 (46%)), fever (n = 9 (35%)), dry/sore throat (n = 3 (12%)), rhinorrhea (n = 3 (12%)), anosmia (n = 2 (8%)), chest pain (n = 2 (8%)), diarrhea (n = 2 (8%)), dyspnea (n = 1 (4%)), and headache (n = 1 (4%)). Six patients (23%) were asymptomatic. No patient required supplemental oxygen, intubation, or ECMO. Eight patients (31%) were hospitalized at time of diagnosis, 3 of whom were already admitted for unrelated problems. Post‐transplant immunosuppression was reduced for only 2 patients (8%). All symptomatic patients recovered within 7 days. Our multi‐institutional experience suggests the prognoses of pediatric transplant recipients infected with COVID‐19 may mirror those of immunocompetent children, with infrequent hospitalization and minimal treatment, if any, required.